About Death-associated protein kinase 2
Death-associated protein kinase 2 (DAPK2) is a protein
from Homo sapiens identified by UniProt accession
Q9UIK4, 370 residues long.
MolForge cross-references it against 0 known binders and
70 disease associations.
Target properties
| Protein name | Death-associated protein kinase 2 |
| UniProt accession | Q9UIK4 |
| Gene | DAPK2 |
| Organism | Homo sapiens |
| Length | 370 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (7)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (70)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.49
- death-associated protein kinase 2 measurement · score 0.31
- t-tau:beta-amyloid 1-42 ratio measurement · score 0.29
- breast adenocarcinoma · score 0.24
- cutaneous melanoma · score 0.15
- hemoglobin measurement · score 0.10
- erythrocyte count · score 0.10
- hematocrit · score 0.09
- cystitis · score 0.07
- mean corpuscular volume · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UIK4-F1 | alphafold | PREDICTED | 86.44 | — |
Amino-acid sequence (370 residues)
MFQASMRSPN MEPFKQQKVE DFYDIGEELG SGQFAIVKKC REKSTGLEYA AKFIKKRQSR ASRRGVSREE IEREVSILRQ VLHHNVITLH DVYENRTDVV LILELVSGGE LFDFLAQKES LSEEEATSFI KQILDGVNYL HTKKIAHFDL KPENIMLLDK NIPIPHIKLI DFGLAHEIED GVEFKNIFGT PEFVAPEIVN YEPLGLEADM WSIGVITYIL LSGASPFLGD TKQETLANIT AVSYDFDEEF FSQTSELAKD FIRKLLVKET RKRLTIQEAL RHPWITPVDN QQAMVRRESV VNLENFRKQY VRRRWKLSFS IVSLCNHLTR SLMKKVHLRP DEDLRNCESD TEEDIARRKA LHPRRRSSTS
Explore Death-associated protein kinase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets